By Q. Mamuk. Florida Atlantic University. 2019.
The center of the diamond is at the pooled point estimate purchase geriforte 100 mg otc, and its horizontal tips show the confidence interval geriforte 100 mg without a prescription. Neuropathic pain 69 of 92 Final Update 1 Report Drug Effectiveness Review Project Funnel plot: A graphical display of some measure of study precision plotted against effect size that can be used to investigate whether there is a link between study size and treatment effect geriforte 100 mg with amex. Half- life: The time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%. Harms: See Adverse Event Hazard ratio: The increased risk with which one group is likely to experience an outcome of interest. For example, if the hazard ratio for death for a treatment is 0. Head-to-head trial: A trial that directly compares one drug in a particular class or group with another in the same class or group. Health outcome: The result of a particular health care practice or intervention, including the ability to function and feelings of well-being. For individuals with chronic conditions – where cure is not always possible – results include health-related quality of life as well as mortality. Heterogeneity: The variation in, or diversity of, participants, interventions, and measurement of outcomes across a set of studies. I is the proportion of total variability across studies that is due to heterogeneity and not chance. It is calculated as (Q-(n- 1))/Q, where n is the number of studies. Incidence: The number of new occurrences of something in a population over a particular period of time, e. Indication: A term describing a valid reason to use a certain test, medication, procedure, or surgery. In the United States, indications for medications are strictly regulated by the Food and Drug Administration, which includes them in the package insert under the phrase "Indications and Usage". Indirect analysis: The practice of using data from trials comparing one drug in a particular class or group with another drug outside of that class or group or with placebo and attempting to draw conclusions about the comparative effectiveness of drugs within a class or group based on that data. For example, direct comparisons between drugs A and B and between drugs B and C can be used to make an indirect comparison between drugs A and C. Intent to treat: The use of data from a randomized controlled trial in which data from all randomized patients are accounted for in the final results. Trials often incorrectly report results as being based on intent to treat despite the fact that some patients are excluded from the analysis. Internal validity: The extent to which the design and conduct of a study are likely to have prevented bias. Generally, the higher the interval validity, the better the quality of the study publication. Inter-rater reliability: The degree of stability exhibited when a measurement is repeated under identical conditions by different raters. Intermediate outcome: An outcome not of direct practical importance but believed to reflect outcomes that are important. For example, blood pressure is not directly important to patients but it is often used as an outcome in clinical trials because it is a risk factor for stroke and myocardial infarction (hear attack). Masking: See Blinding Mean difference: A method used to combine measures on continuous scales (such as weight) where the mean, standard deviation, and sample size are known for each group. Meta-analysis: The use of statistical techniques in a systematic review to integrate the results of included studies. Although the terms are sometimes used interchangeably, meta-analysis is not synonymous with systematic review. However, systematic reviews often include meta-analyses. Meta-regression: A technique used to explore the relationship between study characteristics (for example, baseline risk, concealment of allocation, timing of the intervention) and study results (the magnitude of effect observed in each study) in a systematic review. Mixed treatment comparison meta analysis: A meta-analytic technique that simultaneously compares multiple treatments (typical 3 or more) using both direct and indirect evidence. The multiple treatments form a network of treatment comparisons. Also called multiple treatment comparisons, network analysis, or umbrella reviews. Monotherapy: the use of a single drug to treat a particular disorder or disease. Multivariate analysis: Measuring the impact of more than one variable at a time while analyzing a set of data. N-of-1 trial: A randomized trial in an individual to determine the optimum treatment for that individual. Noninferiority trial: A trial designed to determine whether the effect of a new treatment is not worse than a standard treatment by more than a prespecified amount. Nonrandomized study: Any study estimating the effectiveness (harm or benefit) of an intervention that does not use randomization to allocate patients to comparison groups. There are many types of nonrandomized studies, including cohort studies, case-control studies, and before- after studies. Null hypothesis: The statistical hypothesis that one variable (for example, treatment to which a participant was allocated) has no association with another variable or set of variables. Number needed to harm: The number of people who would need to be treated over a specific period of time before one bad outcome of the treatment will occur. The number needed to harm (NNH) for a treatment can be known only if clinical trials of the treatment have been performed. Number needed to treat: An estimate of how many persons need to receive a treatment before one person would experience a beneficial outcome. Observational study: A type of nonrandomized study in which the investigators do not seek to intervene, instead simply observing the course of events. Odds ratio: The ratio of the odds of an event in one group to the odds of an event in another group. Off-label use: When a drug or device is prescribed outside its specific FDA-approved indication, to treat a condition or disease for which it is not specifically licensed. Outcome: The result of care and treatment and/ or rehabilitation. In other words, the change in health, functional ability, symptoms or situation of a person, which can be used to measure the Neuropathic pain 71 of 92 Final Update 1 Report Drug Effectiveness Review Project effectiveness of care/treatment/rehabilitation.
However cheap geriforte 100mg line, for many combinations the interactions are uncertain order geriforte 100 mg visa, unknown or can only be assumed based on theoretical calculations (K) cheap geriforte 100mg online. In these cases, use might still be safe and should be controlled by TDM. The first part is focused on ART/ART interactions, the second part on those between ART and concomitant medications. Among the INSTIs, elvitegravir is listed as the fixdose tablet Stribild (STB). Cobicistat stand-alone (Tybost) which is approved in combinations with atazanavir and darunavir, is not listed, as well as irrelevant drugs such as d4T, ddI indinavir, nelfi- navir. All PIs are assumed to be given boosted with ritonavir or cobicistat. T-20 is only mentioned in the first part as there are no known relevant interactions. This chapter is intended as a tool to support rapid decision making in the daily prac- tice, but should not replace a literature search. On rare occasions, drug combina- tions with known adverse effects might be unavoidable due to a lack of alternatives. In these cases, close monitoring (including TDM) is necessary. Individual questions regarding interactions can be answered by experts (e. Abbreviations: + Combination of these drugs possible K Potential interactions or unknown, combination of these drugs is often possible, therapeutic drug monitoring suggested L Combination of these drugs should be avoided or is contraindicated ↑ up to 50% increased drug levels, ↑↑ up to 100%, ↑↑↑ >100% ↓ up to 50% decreased drug levels, ↓↓ up to 100%, ↓↓↓ >100% BID Twice daily (TID = Three times daily. QD = Once daily) TDM Therapeutic drug monitoring Drug-Drug Interactions 659 Part 1: ART + ART NRTIs + NRTIs 3TC ABC FTC TDF AZT 3TC + L1 + + ABC K + FTC L1 + + + TDF + K + K AZT + + + K 1 Antagonism NRTIs + NNRTIs 3TC ABC FTC TDF AZT EFV + + + + + ETV + + + + + NVP + + + + + RPV + + + + + NRTIs + PIs 3TC ABC FTC TDF AZT ATV + + + K1 + DRV + + + +2 + FPV + + + + + IDV + + + + + LPV + K3 + +2 + NFV + + + + + RTV + + + K + SQV + + + + + TPV + K3 + + K3 1 ATV ↓, TDF ↑, ATV always boosted 2TDF ↑, caveat: combination with nephrotoxic drugs, increased nephrotoxicity possible 3 NRTI ↓ (unknown relevance) NRTIs + EIs/INSTIs 3TC ABC FTC TDF AZT T-20 DTG MVC RAL STB as a single tablet regimen should not be coadministered with other ARTs 660 Drugs NNRTIs + EIs/INSTIs, EIs/INSTIs + EIs/INSTIs EFV ETV NVP RPV T-20 DTG MVC RAL EFV L, NNRTIs + K4 K1 K2 ETV should not + L5 K1 + NVP be combined + L RPV with each other T-20 DTG L4 L5 L4 L MVC K1 K1 3 RAL K2 L +3 1 MVC ↓↓, increase MVC to 2 x 600 mg/d, if not combined with PI or potent CYP3A4 inhibitor 2 RAL ↓, relevance unclear 3 RAL ↓, MVC ↓, probably without clinical rele-vance 4 DTG↓increase DTG to 50mg BID 5 DTG↓no combination with EFV without co-administration of ATV, LPV or DRV STB as a single tablet regimen should not be coadministered with other ARTs NNRTIs + PIs, EIs/INSTIs + PIs EFV ETV NVP RPV T-207 DTG MVC RAL ATV K1 L1 KK+ + K2 K DRV K + + + + + K2 + FPV KL KK3 + K8 + + LPV K4 + K4 K2 + RTV KK+ K + KK2 + SQV K +5 KK+ KK2 + TPV + L6 + KKK8 + K 1 ATV ↓↓, ATV always boosted 2 MVC ↑↑↑, reduce MVC to 2 x 150 mg/d 3 FPV ↑↑, relevance unclear, monitor FPV levels 4 LPV ↓, increase LPV to 2 x 3 tablets (controversial in combination with NVP, use TDM) 5 SQV ↓↓, always boosted 6 ETV ↓↓, TPV↑, combination therefore not recommended 7 T-20 can be increased by PIs, PIs by T-20, too, no clinical relevance; TDM if problems 8 DTG↓, increase DTG to 50 mg BID PIs + PIs ATV DRV FPV LPV RTV SQV TPV ATV + KK 1 L DRV + KL+ LL FPV KK K 2 L LPV KLK L RTV SQV +1 L +2 L TPV LLLL+ L 1 ATV ↑, SQV ↑, combination well tolerated 2 FPV with 200 mg RTV, combination possible Comment: The combination of two PIs is probably not more effective compared to second generation PIs (DRV and TPV) Drug-Drug Interactions 661 Part 2: ART + concomitant medications Gastrointestinal agents NRTIs/NNRTIs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Cimetidine K K2 Famotidine K2 Loperamide MCP K Mesalazine K + KK Ondansetrone 1 +1 +1 K Ranitidine K2 PPIs L3 1 NNRTIs are strong enzyme inductors, ondansetrone levels can be decreased 2 RPV should not be coadministered with H2-blocking agents, alternatively H2-blocker >12h before or 4h after RPV. MCP = metoclopramide, PPIs = proton pump inhibitors Antiarrhythmic drugs Most PIs increase the drug levels of antiarrhythmic drugs. In combination with NNRTIs the levels might be fluctuating. Antiarrhythmic drugs should be introduced with the lowest possible dosage. Calcium channel inhibitors will be discussed separately. KKKKKLLLL Lithium Mirtazapine KKKKKKKK1 + Nortriptyline KKKKK Paroxetine KKKKK+1 Sertraline KKKKKK1 Trazodone K1 KK+ Venlafaxine K1 KK+ 1 CNS-effects of EFV can be increased Comment: No data exists for most antidepressants and their interactions with NRTIs. PIs/EIs/INSTIs ATV DRV FPV LPV SQV TPV MVC STB DTG RAL Amitriptyline1 LKLKKKKK7 + K Bupropion KKKKKKKK1 7 + K Citalopram4 KKKKKKKK7 + K Desipramine1 KKK+ KKKK7 + K Doxepin4 KKKKKKKK7 + K Fluoxetin4 KKKKKKKK7 + K St. LLLLLLLL Lithium K Mirtazapine KKKKKKKK7 + K Nortriptyline1 KKKKKKKK7 + K Paroxetine K2 K2 K2 L4 K4 K4 KK7 + K Sertaline KK KLKK KK3 4 7 + K Trazodone LL LKLL4 + K7 Venlafaxine5 KKKKKKKK7 1 Tricyclic antidepressants and boosted PIs: PI ↑, antidepressant ↑ 2 Paroxetine ↓–↓↓, adjust if applicable 3 Sertraline ↓, adjust if applicable 4 Antidepressant↑, titrate dose! STB should not be combined with Astemizole and Terfenadine. Potential interactions with other antihistamines, consider Cetirizine. PIs/NNRTIs ATV DRV FPV LPV SQV TPV EFV ETV NVP RPV Astemizole1 LLLLLLLLKK Cetirizine 2 Fexofenadine KKKKKKKKK2 + Loratadine KKKKKKKK Terfenadine1 LLLLLLLLKK 1 Cave at: Arrhythmia 2 CNS-effects of EFV can be increased Comment: No relevant interactions with NRTIs 666 Drugs Antihypertensive therapy Calcium-channel blockers (CCB) can be increased (separate chapter), especially in combination with PIs or STB. In combination with NNRTIs variations in drug levels are possible. The combination of beta blockers and Atazanavir can lead to QT-prolongation. There are interactions between STB and beta blockers, their levels may increase. Anticonvulsants NRTIs/NNRTIs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Carbamazepine KKKKKK LK L1,2 1 Gabapentine 2 Lamotrigine 2 Levetiracetam L Oxcarbazepine KKL Phenobarbital + K KKLKL Phenytoin + K KKLK+ Pregabaline K + KK+ + + + + Valproic acid + K K3 + + K + 1 EFV ↓, NVP ↓, avoid combination or monitor closely (TDM) 2 CNS-effects of EFV can be increased 3 AZT ↑↑, monitor for side effects PIs/EIs/INSTIs ATV DRV FPV LPV SQV TPV MVC STB DTG RAL Carbamazepine K1 K1 K1 K1 K1 K1 KLKK3 Gabapentine + + + + + + + + + + Lamotrigine K 2 Levetiracetam Oxcarbazepine KKKKKK+ KK3 + Phenobarbital KLKKKKKLKK3 Phenytoin KLLKKKKLKK3 Pregabalin Valproic acid K K + KKK+ K 1 PIs ↓, Carbamazepine ↑, avoid if possible or monitor closely (TDM) 2 Lamotrigine ↓, increase if necessary 3 Avoid this combination, DTG↓ Drug-Drug Interactions 667 Anthelmintic agents NRTIs/NNRTIs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Albendazole KKKK+ Diethylcarbamazine Ivermectin + + + + + KKK+ Levamisole (Ergamisol) Mebendazole KKKK+ Niclosamide Oxamniquine Praziquantel + + + + + KKK+ Pyrantel Suramin sodium K Triclabendazole + + + + + KKKK PIs/EIs/INSTIs ATV DRV FPV LPV SQV TPV MVC STB DTG RAL Albendazole KKKKKK+ K Diethylcarbamazine Ivermectin KKKKKK+ K Levamisole (Ergamisol) Mebendazole KKKKKK+ K Niclosamide Oxamniquine KKK+ KK+ K Praziquantel KKKKKK+ K Pyrantel Suramin sodium Triclabendazole KKKKKKKK 668 Drugs Antimycotic agents NRTIs/NNRTIs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Amphoter. B K + KLK1 1,2 Caspofungin KKKKK K1,2 8 K8 K8 + Fluconazole K1,2,3 K4 K Flucytosin K + KKK Itraconazole K6 K5 L4 K Ketoconazole K6 K5 L7 K Posaconazole + K KL K10 5 K4 K Terbinafine KKKKK Voriconazole KKKKKK K6,9 5 K4 K 1 Caveat: additive nephrotoxicity possible 2 Increased hematotoxicity 3 AZT ↑↑, Fluconazole ↓ 4 NVP ↑↑, monitor liver function tests; in combination with azoles Fluconazole still preferred 5 azoles increase ETR levels, relevance unclear 6 NNRTIs ↑, azoles ↓ 7 NVP ↑, Ketoconazole ↓↓ 8 Caspofungin ↓, dose 70mg/d recommended. B KK+ K Caspofungin KKKK+ KK K Fluconazole K1 + K Flucytosine K K Itraconazole2 KKKK3 + KK K4 Ketoconazole2 KK+ K + KK K4 Posaconazole L7 KKKKKKK6 Terbinafine KK+ K Voriconazole5 KLKLKKKK6 1 Fluconazole ↑↑, do not excess 200 mg/d 2 PIs ↑, Itra-/Ketoconazole ↑, avoid doses >200 mg/d 3 LPV ↑, Itraconazole ↑; avoid doses >200 mg Itrac. Calcium channel antagonists (CCB) The serum levels of CCB can be increased, especially if combined with PIs. Lercarnidipine is contraindicated in combination with boosted PIs. In combination with NNRTIs serum levels might be fluctuating. Start CCB at low dose and titrate to full effect, monitor BP or discuss alternatives. Drug-Drug Interactions 669 NRTIs/NNRTIs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Amlodipine KKK+ Diltiazem KKKK Felodipine KKK+ Lercarnidipine KKK+ Nifedipine KKK+ Verapamil KKKK PIs/EIs/INSTIs ATV DRV FPV LPV SQV TPV MVC STB DTG RAL Amlodipine KKKKKKKK+ K Diltiazem KKKKKKKK+ K Felodipine KKKKKK+ K Lercarnidipine LLLLLL+ L Nifedipine KKKKKKKK+ K Verapamil KKKKKKKK+ K Immunosuppressants/Chemotherapeutic agents NRTIs/NNRTIs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Azathioprine K1 Carboplatin K + KKK2 1 Ciclosporin KKKKKKK2 3 3 K3 K Cisplatin K + KKK2 1 Cyclophosph. KKKKKKKK1 + Cytarabine K1 Daunorubicin K1 K Docetaxel KKKK Doxorubicine K1 KKK+ Etoposide K1 KKK+ Fluorouracil + KKKK1 Gemcitabine K1 Interferon K1 Interleukin 2 + + + K2 K1 Irinotecan K1 KKK+ Methotrexate5 KKKKK2 1 KKKK Mycophenolat Oxaliplatin Paclitaxel KKKKK1 +4 +4 +4 + 670 Drugs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Sirolimus K3 K3 K3 + Tacrolimus K + KK2 + K3 K3 K3 K Tam oxifen KKK+ Vinblastine K + KKKKKK+ Vincristine K + KKKKKK+ 1 AZT: Hematotoxicity, avoid if possible 2 Additive nephrotoxicity possible 3Immunosuppressants ↑–↓, always TDM and dose adjustments! PIs/EIs/INSTIs ATV DRV FPV LPV SQV TPV MVC STB DTG RAL Azathioprin Carboplatin Ciclosporin1 KKLKKKKK Cisplatin K Cyclophosph. KK+ K Cytarabine Daunorubicin K KL K6 Docetaxel KKKKKKKK Doxorubicine K3 K3 K3 K3 K3 + K K Etoposide K3 K3 K3 K3 K3 K3 KK+ K Fluorouracil Gemcitabine Interferon Interleukin 2 K Irinotecan L2 K2 K2 K2 K2 K4 + K Methotrexate6 KKKKKKKKKK Mycophenol. TDM of MMF recommended Drug-Drug Interactions 671 Contraception The serum levels of both ethinylestradiol and norethindrone can be very fluctua- tion especially in combination with (boosted) PIs. Therefore the use of oral contra- ceptives containing these hormones might be unsafe. Furthermore their levels can be fluctuating if combined with efavirenz and nevirapine. For these reasons as well as for STD and HIV transmission prophylaxis oral contraceptives should always be combined with an additional method of contraception, preferably a condom. Antimalarials/Antiprotozoals NRTIs/NNRTIs 3TC ABC FTC TDF AZT EFV ETV NVP RPV Artemisin K1 KKKK Atovaquone K1 K K Quinine KKKK Choroquine K Halofantrine KKKK Lumefantrine KKKKK K Mefloquine Pentamidine K2 + K K Primaquine KKKK Proguanil Pyrimethamin K + KKK3 1 AZT ↑, monitor for toxicity 2 Caveat: Nephrotoxicity 3 Caveat: Hematotoxicity PIs/EIs/INSTIs ATV DRV FPV LPV SQV TPV MVC STB DTG RAL Artemisin KKK+ KKKK Atovaquone K + + K + K + + + + Quinine KKKKKKKK Chloroquine Halofantrine LLLLLL+ K Lumefantrine KKKKLL+ K Mefloquine K Pentamidine K Primaquine Proguanil Pyrimethamine 672 Drugs Phosphodiesterase type 5 inhibitors Combinations of most PDE5 inhibitors (e. Thus they should be started care- fully with a reduced (usually half) dose every 48 to 72 hours.